Posted by Michael Wonder on 04 Nov 2021
Opiant receives FDA fast track designation for OPNT003, nasal nalmefene, for treatment of opioid overdose
4 November 2021 - Fast track designation further underscores the potential for OPNT003 to represent a major advance in the treatment of opioid overdose as opioid overdose deaths surge.
Opiant Pharmaceuticals today announced that the U.S. FDA has granted fast track designation for OPNT003, nasal nalmefene, its investigational treatment for opioid overdose.
